|Bid||5,932.00 x 6100|
|Ask||5,934.00 x 13000|
|Day's Range||5,916.00 - 5,962.00|
|52 Week Range||4,928.50 - 6,540.00|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||34.91|
|Earnings Date||Apr 26, 2019|
|Forward Dividend & Yield||2.15 (3.51%)|
|1y Target Est||78.83|
Five years ago this week, AstraZeneca boss Pascal Soriot was embarking on the fight of his life. The urbane Frenchman, who learned how to hold his own growing up in the Parisian banlieues, had to marshal his forces to see off an attempt by Pfizer, the US pharma group, to take over the company he had headed for just 18 months. Much of his defence against this transatlantic predator rested on a personal appeal to investors and AstraZeneca’s board to trust that he could breathe new life into its faltering R&D operation, as it faced one of the more vertiginous “patent cliffs” in the industry.
The blue-chip index ended a lacklustre session about flat, lagging its European peers, while the FTSE 250 held on to its six-month high with a 0.5 percent rise as a stronger pound also aided. The pound's gains followed upbeat comments from Britain's foreign minister Jeremy Hunt on talks between the government and the opposition Labour Party to find a consensus over Brexit.
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Oncology portfolio growth trends During AstraZeneca’s (AZN) fourth-quarter earnings investor presentation, the company highlighted the potential of its oncology drug,
(Reuters) - Britain's main index lost ground on Monday as miners and oil majors fell, more than offsetting gains in bank stocks. The FTSE 100 was 0.2 percent lower, lagging its European and Asian counterparts, ...
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Earnings guidance On its fourth-quarter earnings conference call, Pfizer (PFE) said that it expected its 2019 adjusted diluted EPS to be $2.82–$2.92, which doesn’t
Pfizer or AstraZeneca: Which Is a Better Pick in April?Stock price movementsOn April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37, and 9.04% below its 52-week high of
History favors a sustained rally after the strongest first quarter in a decade, but challenges remain as growth slows in the U.S., China and Europe.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! There are a number of reasons that attract investors towards large-cap companies such as AstraZeneca PLC (LON:AZN), with a ma...
Moody's Investors Service says that Daiichi Sankyo Company, Limited's (A2 stable) announced collaboration with AstraZeneca PLC (A3 stable) on Daiichi Sankyo's trastuzumab deruxtecan (DS-8201) breast cancer drug is beneficial to the growth of the Japanese company's oncology franchise. On 29 March, Daiichi Sankyo announced the collaboration with AstraZeneca on the global development and commercialization of DS-8201, the most promising drug in Daiichi Sankyo's pipeline.
Moody's Investors Service (Moody's) has today affirmed AstraZeneca PLC's (AstraZeneca) A3 senior unsecured rating, its (P)A3 senior unsecured medium-term note program rating, its (P)A3 senior unsecured shelf rating and the short-term rating commercial paper at P-2. Concurrently, Moody's affirmed Zeneca Wilmington Inc.'s A3 senior unsecured rating.
AstraZeneca plc (NYSE: AZN ) shares, which have gained about 9 percent year-to-date, were seeing incremental upside Monday in the wake of a company announcement. The shares also received a shot in the ...
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational MEK 1/2 inhibitor and potential new medicine selumetinib.
The pan-European STOXX 600 index closed up 0.6 percent, having earlier hit session highs on encouraging signals from U.S.-China trade talks. The benchmark clocked its best quarter in four years, although gains in March were lower than in the previous two months as a bruising trade war which contributed to a slowdown in global growth and the chaos around Brexit hit sentiment. All sub-sectors within the pan-regional benchmark ended the quarter higher, led by the retail sector's 20 percent surge over the last three months.
The FTSE 100 added 0.6 percent to post its third straight month of gains and its first quarterly rise since June 2018. This led to blue-chip housebuilders, considered particularly sensitive to Brexit developments, hitting session lows.
Daiichi announced late Thursday that it has entered into a global development and collaboration agreement with AstraZeneca regarding its lead antibody drug conjugate [fam-] trastuzumab deruxtecan, or DS-8201. The drug is an investigational candidate that is being developed for multiple HER2-expressing cancers, including breast and gastric cancer, and additional development in non-small cell lung and colorectal cancer.
The deal on the drug known as trastuzumab deruxtecan sent shares in Japan's Daiichi soaring 16 percent, its daily limit, to a record high on Friday. Daiichi's stock has climbed 45 percent this year on optimism about the treatment. Britain's AstraZeneca plans to use some of the proceeds of a $3.5 billion share issue to fund the deal.
LONDON (AP) — Shares in drug maker Daiichi Sankyo soared after AstraZeneca agreed to pay the Japanese company up to $6.9 billion as part of an agreement to develop and market a potentially "transformative" cancer treatment.
SECTORFOCUS BLOG That Friday feeling. Stocks are looking up Friday morning, with Dow Jones Industrial Average and Nasdaq Composite futures up 0.5% and the S&P 500 rising 0.4% ahead of the open. While global economic worries still remain, investors were optimistic that a fresh round of U.